A Phase 2 interventional study of Alirocumab and Placebo (for alirocumab) in Hypercholesterolemia, sponsored by Sanofi. Completed at 4 sites in Japan. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-10-04.
Sponsored by Sanofi · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing alirocumab in Hypercholesterolemia — 1 open to participants now, 2 under way, none of them phase 3. alirocumab · Hypercholesterolemia.
Among the 43 studies testing alirocumab in Hypercholesterolemia, this one is the 24th largest by enrollment, is one of 6 that started in 2013, is one of 9 in phase 2, and was the 22nd registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →1 of the 43 studies testing alirocumab in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:
University Medical Centre Ljubljana · Sites in Slovenia
Ages 18+
By country, each count listing its studies:
alirocumab: first FDA approval 2015 (PRALUENT), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 20 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 6 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 100 is close to the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 107 across the 43 interventional studies. Of the 40 that completed or were terminated, 30 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 43 have an industry lead sponsor. The 6 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
38 studies in Hypercholesterolemia by Sanofi: none open now, none under way, none of them phase 3. Of 38 finished, 22 (58%) have results posted.
Among the 38 studies in Hypercholesterolemia by Sanofi, this one is the 25th largest by enrollment, is one of 5 that started in 2013, is one of 6 in phase 2, and was the 22nd registered.
Sanofi’s Hypercholesterolemia studies by the year they started, since 2007.
2 of the studies testing alirocumab in Hypercholesterolemia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07477704Regeneron PharmaceuticalsA Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia | 2026-12-29 |
| NCT07581808University Medical Centre LjubljanaDual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention | 2027-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 43 studies testing alirocumab in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 38 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Alirocumab (SAR236553/REGN727) is a fully human monoclonal antibody that binds proprotein convertase subtilisin/kexin type 9 (PCSK9).
Primary Objective of the study:
To evaluate the effect of alirocumab on low-density lipoprotein cholesterol (LDL-C) levels after 12 weeks of treatment in comparison with placebo in participants with LDL-C ≥100 mg/dL (≥2.59 mmol/L) on ongoing stable atorvastatin therapy.
Secondary Objectives:
The duration of study participation depended on the status of the participant at screening: 21 to 27 weeks including a screening/run-in period of 1 to 7 weeks, a double-blind treatment period of 12 weeks, followed by an 8-week follow-up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
OR
Exclusion criteria:
LDL-C \<100 mg/dL (\<2.59 mmol/L)
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Placebo (for alirocumab) every 2 weeks (Q2W) for 12-weeks in combination with atorvastatin stable dose.
Drug: Placebo (for alirocumab) · Drug: Atorvastatin
Alirocumab 50 mg Q2W for 12-weeks in combination with atorvastatin stable dose.
Drug: Alirocumab · Drug: Atorvastatin
Alirocumab 75 mg Q2W for 12-weeks in combination with atorvastatin stable dose.
Drug: Alirocumab · Drug: Atorvastatin
Alirocumab 150 mg Q2W for 12-weeks in combination with atorvastatin stable dose.
Drug: Alirocumab · Drug: Atorvastatin
Two SC injections in the abdomen only
Also known as: SAR236553, RGEN727
Two subcutaneous (SC) injections in the abdomen only Route of administration: subcutaneous injection (1 mL) in the abdomen
Orally once daily at a stable dose of 5 to 20 mg as background therapy Route of administration: oral administration in the evening
Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis
Calculated LDL-C values were obtained using the Friedewald formula. Baseline adjusted least squares (LS) means and standard errors were estimated using an analysis of covariance (ANCOVA) model including available post-baseline data on treatment from first investigational product (IP) injection up to 21 days after last IP injection (on-treatment analysis). Missing Week 12 data were imputed by last observation carried forward \[LOCF\] method.
Time frame: Baseline to Week 12 (LOCF)
Absolute Change From Baseline in Calculated LDL-C (mmol/L) at Week 12 - On-Treatment Analysis
Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.
Time frame: Baseline to Week 12 (LOCF)
Absolute Change From Baseline in Calculated LDL-C (mg/dL) at Week 12 - On-Treatment Analysis
Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.
Time frame: Baseline to Week 12 (LOCF)
Percentage of Participants Achieving Calculated LDL-C <100 mg/dL (2.59 mmol/L) and < 70 mg/dL (1.81 mmol/L) at Week 12 - On-Treatment Analysis
Time frame: Week 12 (LOCF)
Percent Change From Baseline in Total Cholesterol, High-Density Lipoprotein Cholesterol (HDL-C), Non-HDL-C, and Apolipoprotein B (Apo-B) at Week 12 - On-Treatment Analysis
Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.
Time frame: Baseline to Week 12 (LOCF)
Percent Change From Baseline in Fasting Triglycerides and Lipoprotein (a) at Week 12 - On-Treatment Analysis
Since the assumptions of normal distribution and equality of variances were not verified for the lipid parameters, percent changes were expressed as median (inter-quartile range).
Time frame: Baseline to Week 12 (LOCF)
Absolute Change From Baseline in Apolipoprotein B/Apolipoprotein A-1 (ApoB/ApoA-1) Ratio at Week 12 - On-Treatment Analysis
Adjusted LS mean and standard errors were estimated using the same ANCOVA as for primary endpoint.
Time frame: From Baseline to Week 12 (LOCF)
The study was conducted at 4 centers in Japan. Overall, 162 participants were screened between March 2013 and August 2013, 62 of whom were run-in/screen failures, mainly due to exclusion criteria met.
| Milestone | Placebo | Alirocumab 50 mg Q2W | Alirocumab 75 mg Q2W | Alirocumab 150 mg Q2W |
|---|---|---|---|---|
| Started | 25 | 25 | 25 | 25 |
| Treated | 25 | 25 | 25 | 25 |
| Completed | 23 | 25 | 25 | 23 |
| Not completed | 2 | 0 | 0 | 2 |
| Withdrew: Adverse event | 0 | 0 | 0 | 2 |
| Withdrew: Poor compliance to protocol | 1 | 0 | 0 | 0 |
| Withdrew: Consent withdrawn by participant | 1 | 0 | 0 | 0 |
Calculated LDL-C values were obtained using the Friedewald formula. Baseline adjusted least squares (LS) means and standard errors were estimated using an analysis of covariance (ANCOVA) model including available post-baseline data on treatment from first investigational product (IP) injection up to 21 days after last IP injection (on-treatment analysis). Missing Week 12 data were imputed by last observation carried forward \[LOCF\] method.
| percent change | Placebo | Alirocumab 50 mg Q2W | Alirocumab 75 mg Q2W | Alirocumab 150 mg Q2W |
|---|---|---|---|---|
| Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis | -2.7 ± 3.1 | -54.8 ± 3.1 | -62.3 ± 3.1 | -71.7 ± 3.1 |
Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.
| mmol/L | Placebo | Alirocumab 50 mg Q2W | Alirocumab 75 mg Q2W | Alirocumab 150 mg Q2W |
|---|---|---|---|---|
| Absolute Change From Baseline in Calculated LDL-C (mmol/L) at Week 12 - On-Treatment Analysis | -0.1 ± 0.1 | -1.7 ± 0.1 | -1.9 ± 0.1 | -2.2 ± 0.1 |
Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.
| mg/dL | Placebo | Alirocumab 50 mg Q2W | Alirocumab 75 mg Q2W | Alirocumab 150 mg Q2W |
|---|---|---|---|---|
| Absolute Change From Baseline in Calculated LDL-C (mg/dL) at Week 12 - On-Treatment Analysis | -5.0 ± 3.6 | -67.1 ± 3.6 | -74.6 ± 3.6 | -85.8 ± 3.6 |
| percentage of participants | Placebo | Alirocumab 50 mg Q2W | Alirocumab 75 mg Q2W | Alirocumab 150 mg Q2W |
|---|---|---|---|---|
| LDL-C <100 mg/dL (2.59 mmol/L) | 8.0 | 100.0 | 100.0 | 100.0 |
| LDL-C < 70 mg/dL (1.81 mmol/L) | 0.0 | 84.0 | 84.0 | 88.0 |
Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.
| percent change | Placebo | Alirocumab 50 mg Q2W | Alirocumab 75 mg Q2W | Alirocumab 150 mg Q2W |
|---|---|---|---|---|
| Total Cholesterol | -1.2 ± 2.1 | -31.9 ± 2.1 | -36.3 ± 2.1 | -41.4 ± 2.1 |
| HDL-C | -0.2 ± 2.0 | 5.1 ± 2.0 | 5.0 ± 2.0 | 3.2 ± 2.1 |
| Non-HDL-C | -0.9 ± 2.9 | -46.3 ± 2.9 | -53.1 ± 2.9 | -62.2 ± 2.9 |
| Apo-B | -2.3 ± 3.3 | -43.5 ± 3.3 | -48.6 ± 3.3 | -60.0 ± 3.3 |
Since the assumptions of normal distribution and equality of variances were not verified for the lipid parameters, percent changes were expressed as median (inter-quartile range).
| percent change | Placebo | Alirocumab 50 mg Q2W | Alirocumab 75 mg Q2W | Alirocumab 150 mg Q2W |
|---|---|---|---|---|
| Fasting Triglycerides | 1.3 (-13.1 to 22.5) | -21.1 (-28.2 to 4.2) | -10.7 (-25.0 to 6.5) | -15.0 (-24.1 to 0.0) |
| Lipoprotein (a) | -3.7 (-26.2 to 8.4) | -35.6 (-52.5 to -7.5) | -40.2 (-62.9 to -27.4) | -43.3 (-69.4 to -14.2) |
Adjusted LS mean and standard errors were estimated using the same ANCOVA as for primary endpoint.
| ratio | Placebo | Alirocumab 50 mg Q2W | Alirocumab 75 mg Q2W | Alirocumab 150 mg Q2W |
|---|---|---|---|---|
| Absolute Change From Baseline in Apolipoprotein B/Apolipoprotein A-1 (ApoB/ApoA-1) Ratio at Week 12 - On-Treatment Analysis | 0.02 ± 0.02 | -0.30 ± 0.02 | -0.32 ± 0.02 | -0.38 ± 0.02 |
Collected over All Adverse Events (AE) were collected from signature of the informed consent form up to the final visit (Week 20) regardless of seriousness or relationship to investigational medicinal product (IMP).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 1/25 (4%) | 5/25 (20%) |
| Alirocumab 50 mg Q2W | — | 0/25 (0%) | 11/25 (44%) |
| Alirocumab 75 mg Q2W | — | 0/25 (0%) | 8/25 (32%) |
| Alirocumab 150 mg Q2W | — | 1/25 (4%) | 9/25 (36%) |
| Event | Placebo | Alirocumab 50 mg Q2W | Alirocumab 75 mg Q2W | Alirocumab 150 mg Q2W |
|---|---|---|---|---|
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/25 | 0/25 | 0/25 | 1/25 |
| VertigoEar and labyrinth disorders | 1/25 | 0/25 | 0/25 | 0/25 |
| Event | Placebo | Alirocumab 50 mg Q2W | Alirocumab 75 mg Q2W | Alirocumab 150 mg Q2W |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 2/25 | 6/25 | 6/25 | 4/25 |
| Injection site reactionGeneral disorders | 1/25 | 3/25 | 2/25 | 2/25 |
| CystitisInfections and infestations | 1/25 | 0/25 | 0/25 | 2/25 |
| Back painMusculoskeletal and connective tissue disorders | 1/25 | 2/25 | 0/25 | 1/25 |
| Ligament sprainInjury, poisoning and procedural complications | 1/25 | 0/25 | 0/25 | 2/25 |
Randomized population.
| Age, Continuous(years) | Placebo | Alirocumab 50 mg Q2W | Alirocumab 75 mg Q2W | Alirocumab 150 mg Q2W | Total |
|---|---|---|---|---|---|
| Mean | 58.6 ± 9.2 | 57.8 ± 12.3 | 56.3 ± 12.0 | 58.2 ± 8.8 | 57.7 ± 10.6 |
| Sex: Female, Male(Participants) | Placebo | Alirocumab 50 mg Q2W | Alirocumab 75 mg Q2W | Alirocumab 150 mg Q2W | Total |
|---|---|---|---|---|---|
| Female | 11 | 16 | 12 | 16 | 55 |
| Male | 14 | 9 | 13 | 9 | 45 |
| Low-Density Lipoprotein Cholesterol (LDL-C) in mmol/L(mmol/L) | Placebo | Alirocumab 50 mg Q2W | Alirocumab 75 mg Q2W | Alirocumab 150 mg Q2W | Total |
|---|---|---|---|---|---|
| Mean | 3.13 ± 0.55 | 3.16 ± 0.43 | 3.13 ± 0.43 | 3.12 ± 0.42 | 3.14 ± 0.45 |
| LDL-C in mg/dL(mg/dL) | Placebo | Alirocumab 50 mg Q2W | Alirocumab 75 mg Q2W | Alirocumab 150 mg Q2W | Total |
|---|---|---|---|---|---|
| Mean | 121.0 ± 21.1 | 122.2 ± 16.6 | 120.9 ± 16.7 | 120.5 ± 16.2 | 121.2 ± 17.5 |
The record gives a start of Mar 2013, a primary completion of Jan 2014 and a completion of Jan 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2015, 1 year 8 months after primary completion. A results delay was requested in Jan 2015.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alirocumab